An interventional study of Extended phenotyping and Blood sample for WES in Severe Bacterial Infections, sponsored by Nantes University Hospital. Recruiting at 7 sites in France. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Bacterial Infections with a site in France — 8 open to participants now, 9 under way, none of them phase 3. Bacterial Infections · France.
Among the 49 studies in Bacterial Infections with a site in France, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, and was the 47th registered.
586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →8 of the 49 studies in Bacterial Infections with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier de Saint-Denis · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7 days–90 days
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 3 days–17 yrs
Central Hospital, Nancy, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 1,401 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 142 across the 25 interventional studies, 158 across the 24 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 49 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 4 studies filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Bacterial Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05350813University Hospital, ToulouseImpact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy | 2027-02-02 |
| NCT06618989Assistance Publique - Hôpitaux de ParisDiagnostic Performance of a Combination of Leukocyte Cell Surface Markers in Predicting the Risk of Severe Bacterial Infection in Febrile Children Under Three Months of Age in the Emergency Department: a Pilot Study. | 2027-08-24 |
| NCT07167524University Hospital, RouenEvaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies in Bacterial Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe bacterial infections (SBI) are responsible for significant morbidity and mortality in the paediatric population. There is considerable individual variability in children's susceptibility to developing SBIs. This variability is multifactorial, and the mechanisms at work are not yet fully understood. The investigators of this study therefore propose to study a population of children who had particularly severe bacterial infections requiring hospitalization in a pediatric intensive care unit in France between 2015 and 2018. This study is part of a global approach to understanding the mechanisms favoring the occurrence of IBS in pediatrics.
The study will initially focus on analyzing the clinical phenotype of these children in terms of the type of infection presented, as well as immunologically with an immune workup of all these patients. The investigators also plan to contact each family individually to identify other episodes of personal or family IBS or other elements suggestive of immune deficiency (opportunistic infections, autoimmune manifestations, severe atopy). The investigators will also assess the persistent sequelae since their infectious episode, and their quality of life following this IBS.
In parallel, the genetic analysis of these patients and their parents will be carried out using whole-exome sequencing. The investigators will compare the results with those obtained in 2 IBS-free control populations (N=70 and N=116). The goal is to identify genetic variants that favor the occurrence of IBS in general, and some that are specific to certain bacteria or clinical presentations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients:
For parents:
Exclusion Criteria:
Patient inclus dans l'étude DIABACT IV (NCT02167802) entre 2015 et 2018, dans les suites de son hospitalisation en réanimation pédiatrique en France pour une infection bactérienne sévère.
Other: Extended phenotyping · Other: Blood sample for WES · Other: Blood sample for PBMC freezing · Other: POPC score evaluation · Other: Questionnaire completion
Other: Blood sample for WES · Other: Questionnaire completion
Extended phenotyping (analysis performed at Nantes University Hospital, MANDATORY DELIVERY WITHIN 24 HOURS) = 1 EDTA 3 mL tube for patients included in Nantes.
Blood sample for WES : 1 x 3 mL EDTA tube (if not included in DIABACT IV biocollection)
Blood sample for PBMC freezing integrated into the biocollection: 1 EDTA tube = 3 mL
Assessment of POPC score (Pediatric Overall Performance Category)
Questionnaires completed by parents or children: * SDQ * PedSQL4.0
Identification of innate errors of immunity involved in the development of IBS in pediatrics.
List of rare genetic variants significantly more frequently found in cases than in controls and/or absent in healthy parents.
Time frame: At the enrollment
Identification of inborn errors of immunity involved in the development of IBS and their association with abnormalities of the immune balance,
Time frame: At the enrollment
Identification of rare genetic variants favoring certain clinical types of infection, or certain biological and immunological abnormalities.
Time frame: At the enrollment
Identification of immune deficiencies in patients who have developed a severe bacterial infection
Time frame: At the enrollment
Assessment of sequelae with the POPC sequelae score (Pediatric Overall Performance Category) at a distance from the IBS episode.
The POPC sequelae score is a scale from 1 to 6, with 6 being the worst possible outcome.
Time frame: At the enrollment
Assessment of sequelae at a distance from the IBS episode with the Strengths and Weaknesses Questionnaire (SDQ-Fra).
The SDQ-Fra score is a scale from 0 to 2, with 2 being the worst possible outcome.
Time frame: At the enrollment
Assessment of quality of life at a distance from the IBS episode.
Quality of life will be assessed in this patient population using the Pediatric Quality of Life InventoryTM (scale from 0 to 4, with 4 corresponding to the worst outcome).
Time frame: At the enrollment
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 57 non-industry interventional studies with no phase under Bacterial Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 21 months is below that.
Counting every sponsor, half of 61 studies reached it within 24 months; a quarter within 11 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2027 → Dec 2027 and completion Jun 2029 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.